Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall purchased 150,000 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Immunome Price Performance

Immunome stock traded down $0.56 during trading hours on Friday, reaching $10.87. The stock had a trading volume of 867,170 shares, compared to its average volume of 1,004,945. The company has a market cap of $678.51 million, a price-to-earnings ratio of -1.34 and a beta of 1.90. The business's 50 day moving average price is $11.26 and its 200-day moving average price is $12.65. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaQuest LLC increased its position in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Immunome during the 4th quarter valued at about $274,000. Charles Schwab Investment Management Inc. increased its position in Immunome by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock valued at $4,856,000 after buying an additional 14,775 shares in the last quarter. Johnson Financial Group LLC acquired a new stake in Immunome in the fourth quarter worth about $212,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Immunome during the fourth quarter worth about $379,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Analysts Set New Price Targets

IMNM has been the topic of a number of research reports. Piper Sandler reduced their target price on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Stephens assumed coverage on Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $28.60.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.